US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.
The company expects to file an sNDA for plaque psoriasis next year.
Sales rose 5% compared to the same period last year.
Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also reaped blockbuster sales for Gilead.
Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."
The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.
The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.
The company said it plans to file its rare-disease drug with the FDA later this year, for a 2015 review.
GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."
Pfizer and Teva's settlement puts generic Celebrex on the market by December.